… for the P2Y12 inhibitors. The onset of action is significantly delayed in STEMI and cardiogenic
shock patients for all oral P2Y12 inhibitors. Following intestinal absorption, ticagrelor does …

… Conversely, we examined efficacy and safety of P2Y 12 inhibitors in a large cohort of patients
using standard drug dosages in a population exclusively composed by ACS patients and …

… available on oral P2Y 12 inhibitors in acute coronary syndrome. We aimed to evaluate …
safety profile of prasugrel, ticagrelor, and clopidogrel in acute coronary syndrome by a meta-…

… on ischemic and bleeding events in elderly ACS patients has been … optimal P2Y12 inhibitor
in elderly patients with ACS by assessing the efficacy and safety of potent P2Y12 inhibitors …

… inhibitors currently recommended for the treatment of patients with ACS (clopidogrel, prasugrel,
and ticagrelor… standard selection of P2Y 12 inhibitors among patients with ACS were also …

… The goal in this subset of ACS patients would be to achieve adequate platelet inhibition
and prevention of further platelet aggregation and thrombosis while awaiting invasive …

… ticagrelor for ACS patients at moderate to high ischemic risk regardless of the initial treatment,
but prasugrel for ACS patients … 12 inhibitors with that of clopidogrel in patients with ACS, …

… ACS patients undergoing ad hoc PCI who were not pre-treated with a P2Y 12 inhibitor, ticagrelor
… tested with ticagrelor in the context of a randomized study of non–ST-segment elevation …

… use of more potent P2Y12 inhibitors led to similar relative benefits in reducing the composite
efficacy outcome of death, MI, or stroke in elderly and nonelderly ACS patients but also to …

… Despite supportive evidence from subgroups of large trials after acute coronary syndrome
for clopidogrel or ticagrelor,29 30 a DAPT regimen remains inconsistently implemented in …